For instance, EMBER-4 is a phase III clinical trial investigating the efficacy of imlunestrant compared to standard hormone therapy in patients with a history of high-risk ER+ HER2− breast cancer who have received standard endocrine therapy for two to five years (NCT05514054). Here, ESR1 is linked to breast carcinoma.